Supreme Court Unanimously Reverses Federal Circuit in Hikma v. Amarin

The decision rejected Amarin’s attempt to characterize Hikma’s compliance with statutory labeling requirements and standard industry practices as evidence of affirmative steps to induce patent infringement. The ruling resets the legal standard for induced infringement in the pharmaceutical context and materially strengthens the section viii skinny-label pathway for generic market entry.

Procedural Background

Amarin Pharma, Inc. developed Vascepa, a drug containing the active ingredient icosapent ethyl. In 2012, the FDA approved Vascepa for the treatment of severe hypertriglyceridemia (the SH indication). At that time, Vascepa’s label included a statement that its effect on cardiovascular mortality and morbidity “has not been determined” (the CV Limitation of Use) because it was not yet approved for cardiovascular uses. Hikma Pharmaceuticals USA Inc. submitted an abbreviated new drug application (ANDA) in 2016 for generic icosapent ethyl. In litigation between the two parties, Amarin’s patents covering the SH indication were invalidated.

While Hikma’s ANDA was still pending, the FDA approved Vascepa for a second, more common use: reducing cardiovascular risk in hypertriglyceridemia patients who already take statins (the CV indication). Amarin removed the CV Limitation of Use from Vascepa’s label and obtained two method-of-use patents for the CV indication. Hikma sought approval of a “skinny label” that included only the SH indication. In 2020, the FDA approved Hikma’s ANDA with the skinny label and assigned an “AB” rating indicating therapeutic equivalence to Vascepa when used according to its labeling.

After Hikma began marketing its generic drug, Amarin filed suit in the District of Delaware alleging that Hikma induced others to infringe Amarin’s CV-indication patents. The district court granted Hikma’s motion to dismiss for failure to state a claim. The Federal Circuit reversed, finding it “at least plausible that a physician could read” the relevant statements “as an instruction or encouragement to” infringe. 

The Legal Standard for Induced Infringement

The Supreme Court reversed the Federal Circuit. The Court framed the controlling inquiry as “whether the defendant actively encouraged infringing uses, not merely whether doctors could plausibly read statements as instructions to infringe.”

A claim for active inducement of infringement under 35 U.S.C. § 271(b) requires three elements: (1) direct infringement by a third party, (2) the inducer must know that the induced acts constitute patent infringement, and (3) the inducer must take active steps to encourage direct infringement. The case turned on the third element. The Court emphasized that “[m]ost fundamentally, ‘inducement must involve the taking of affirmative,’ as opposed to passive, ‘steps to bring about the desired result’ of patent infringement.” To avoid “trenching on regular commerce,” the Court reiterated that “ordinary acts incident to product distribution” are insufficient to support liability.

The Pleading Standard

This case was resolved at the motion-to-dismiss stage under Federal Rule of Civil Procedure 12(b)(6). Under well-established pleading standards, a plaintiff must “state a claim to relief that is plausible on its face.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 570 (2007). That plausibility standard “asks for more than a sheer possibility that a defendant has acted unlawfully.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). If the complaint “pleads facts that are merely consistent with a defendant’s liability, it stops short of the line between possibility and plausibility of entitlement to relief.” 

The Court’s Reasoning

Amarin alleged that the totality of Hikma’s statements in the label, patient information leaflet, website, and press releases encouraged infringing uses. The Court systematically rejected each category, organizing its reasoning around three principles.

In a pointed footnote, the Court observed that Amarin’s arguments mirror the Federal Circuit’s recent trend of focusing on whether relevant statements “could be read by medical providers as instructions to infringe.” The Court expressly rejected that trend, “emphasiz[ing] that the key question is whether a defendant actively encouraged infringement through its statements, not merely how others may understand those statements.”

Obvious Alternative Explanations

First, the Court found that several of Hikma’s statements had an “obvious alternative explanation”: compliance with the law or standard industry practice. Hikma’s label excluded the CV Limitation of Use and included clinical study information regarding patients taking statins. The Court rejected Amarin’s argument that this constituted affirmative inducement to prescribe the generic drug for the patented indication, finding instead that Hikma’s label contained or omitted this information because, by statute, a generic label must be identical to the brand-name label with few exceptions.

Similarly, in press releases, Hikma described its product as “generic Vascepa” or as a generic equivalent to the brand name drug. The Court found that describing a generic product as the “generic equivalent” of the brand-name comparator is “normal industry practice.” The Court declared: 

We decline to put generic manufacturers between a rock and a hard place by turning adherence to the law and industry standards into building blocks for illegal conduct. 

Omissions, Inactions, and Nonfeasance: Not ‘Active’ Inducement

Second, the Court held that Amarin could not rely on “mere omissions, inactions, or nonfeasance” to allege active inducement. Amarin complained that by omitting the CV Limitation of Use from the label and failing to mention in press releases that the generic was approved only for the SH indication, Hikma was encouraging providers to “read between the lines.” While the Court acknowledged that some providers might draw improper conclusions from these omissions, it stated that courts must look for “affirmative ‘statements or actions’” precisely to avoid “trenching on regular commerce” based on such contingent chains of events.

Vague Statements and Speculation About Prescribing Practices

Third, the Court found the remaining statements too vague to support inducement liability. Hikma’s patient information leaflet contained a warning about side effects for people with cardiovascular disease and a disclaimer that medicines are sometimes prescribed for purposes other than those expressly indicated. The Court characterized these as “a warning and a disclaimer, really,” and found them “implausibly roundabout ways to induce medical providers to infringe.”

Hikma’s website described its generic product as “AB” rated (therapeutic equivalent) and described the therapeutic category of the drug as “hypertriglyceridemia” (rather than the indicated “severe hypertriglyceridemia”). The “AB” rating, the Court noted, means only that the product is equivalent to the brand under the conditions specified in the generic’s own label, which excludes unapproved, patented methods of use. Likewise, though the therapeutic category on the website was broader than the approved SH indication, the Court analogized this to describing a treatment for leukemia as a “cancer drug,” not an encouragement to use the drug for non-indicated uses.

Finally, Hikma’s press releases included sales figures that did not distinguish between revenue attributable to the SH indication and the CV indication. Amarin argued this implicitly blessed using the generic for the patented method of use. The Court described the sales figures as the “vaguest” of the alleged statements, requiring numerous speculative leaps. For Amarin’s theory to work, “a medical provider would have to look up and read the press releases, which were directed to investors rather than doctors and pharmacists; have enough background knowledge of pharmaceutical sales to understand the quoted sales figures to be attributable to both the SH-indication and the CV-indication methods of use; and draw from this fact a subtle encouragement to start prescribing Hikma’s generic to hypertriglyceridemia patients who already take statins.” The Court concluded that even if such a chain of events was possible, it is not “plausible.”

Impact on Future Generic Pharmaceutical Cases

This decision carries implications well beyond the specific facts of the Hikma dispute. The controlling legal question for inducement is not how prescribers might read a generic manufacturer’s label or promotional materials; rather, the statements themselves must be designed to affirmatively encourage the patented use. Reorienting the inducement standard from the provider’s potential actions to the speaker’s intent applies across the full range of pharmaceutical inducement cases.

Importantly, the decision strengthens the position of generic manufacturers facing inducement claims. When a generic’s statements have an obvious lawful explanation, such as compliance with FDA labeling requirements or adherence to standard industry practice, those statements alone will not support an inducement claim at the pleading stage. Brand-name plaintiffs can no longer bootstrap statutory compliance or routine marketing into evidence of wrongful intent.

The Court’s treatment of bioequivalence statements is particularly noteworthy. Brand plaintiffs have frequently pointed to AB ratings and therapeutic equivalence descriptors as circumstantial evidence of intent to induce off-label prescribing. The Court rejected this approach, recognizing that such statements are a normal part of generic drug marketing and do not constitute encouragement of patented uses, especially where the manufacturer expressly clarifies that its product is indicated for fewer than all approved indications. Going forward, brand-name companies will likely need to identify affirmative promotional conduct rather than relying on routine labeling and marketing communications to sustain an inducement theory.

Key Takeaways for Generic Manufacturers

• Skinny-label launches are on firmer ground. A generic label that carves out a patented indication under Section viii does not constitute active inducement, even if it retains clinical study data referencing the patented patient population or omits a limitation of use present on the brand’s earlier label.

• Standard marketing language carries less litigation risk. Describing products as “generic [brand name],” referencing AB ratings, using FDA-assigned therapeutic categories, and citing publicly available sales data are now unlikely to support inducement liability absent additional affirmative conduct designed to encourage the patented use.

• Omissions are unlikely to support inducement. A generic manufacturer’s failure to affirmatively disclaim or warn against off-label use should not constitute “active” encouragement of infringement. 

• FDA compliance is a shield. Adherence to statutory labeling requirements provides an “obvious alternative explanation” that weighs heavily against inducement claims at the motion-to-dismiss stage and likely beyond.

• The pleading bar for inducement is substantially higher. Brand plaintiffs must plead affirmative encouragement. Speculative chains of inference are unlikely to survive a motion to dismiss.